An experimental drug developed by Spinifex Pharmaceuticals reduced post-herpetic neuropathic pain by 30% in 58% of patients in a Phase II trial, according to a report in The Lancet. The drug acts on angiotensin II type 2 receptor antagonists, and the company said higher doses could be tested in a larger clinical trial.

Related Summaries